2026-04-23T16:02:02Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/51752024-10-31T12:01:45Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Mateos-Hernandez, Lourdes author Villar, Margarita author Doncel-Perez, Ernesto author Trevisan-Herraz, Marco author Garcia-Forcada, Angel author Romero Ganuza, Francisco author Vazquez, Jesus author de la Fuente, Jose author 2016 Guillain-Barre syndrome (GBS) is an autoimmune-mediated peripheral neuropathy of unknown cause. However, about a quarter of GBS patients have suffered a recent bacterial or viral infection, and axonal forms of the disease are especially common in these patients. Proteomics is a good methodological approach for the discovery of disease biomarkers. Until recently, most proteomics studies of GBS and other neurodegenerative diseases have focused on the analysis of the cerebrospinal fluid (CSF). However, serum represents an attractive alternative to CSF because it is easier to sample and has potential for biomarker discovery. The goal of this research was the identification of serum biomarkers associated with recovery from GBS. To address this objective, a quantitative proteomics approach was used to characterize differences in the serum proteome between a GBS patient and her healthy identical twin in order to lessen variations due to differences in genetic background, and with additional serum samples collected from unrelated GBS (N = 3) and Spinal Cord Injury (SCI) (N = 3) patients with similar medications. Proteomics results were then validated by ELISA using sera from additional GBS patients (N = 5) and healthy individuals (N = 3). All GBS and SCI patients were recovering from the acute phase of the disease. The results showed that Piccolo, a protein that is essential in the maintenance of active zone structure, constitutes a potential serological correlate of recovery from GBS. These results provided the first evidence for the Piccolo's putative role in GBS, suggesting a candidate target for developing a serological marker of disease recovery. Oncotarget. 2016; 7(46):74582-74591 1949-2553 http://hdl.handle.net/20.500.12105/5175 27776345 10.18632/oncotarget.12789 Oncotarget Neuropathy Proteomics Biomarker Guillain-Barre Neurology Immunology and Microbiology Section Immune response Immunity IMMUNE-MEDIATED NEUROPATHIES CEREBROSPINAL-FLUID MULTIPLE-SCLEROSIS PERIPHERAL NEUROPATHIES PEPTIDE IDENTIFICATION MOLECULAR MIMICRY MASS-SPECTROMETRY SYNDROME GBS ANTIGANGLIOSIDE CELLS Quantitative proteomics reveals Piccolo as a candidate serological correlate of recovery from Guillain-Barre syndrome